Literature DB >> 23959108

Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2.

Sirinan Tazen, Karla Figueroa, Justin Y Kwan, Jill Goldman, Ann Hunt, Jacinda Sampson, Laurie Gutmann, Stefan M Pulst, Hiroshi Mitsumoto, Sheng-Han Kuo.   

Abstract

IMPORTANCE: A family with coexistence of spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis (ALS) is described. OBSERVATIONS: Intermediate or full CAG repeat expansions of ATXN2 are associated with ALS. However, no coexistence of spinocerebellar ataxia type 2 and ALS in a family has been reported in the literature.We describe a 47-year-old woman with an 11-year history of ataxia and her paternal uncle with ALS who were evaluated at Columbia University Medical Center since July 2006. Both our patient with ataxia and her uncle with ALS have full pathological CAG repeat expansions of ATXN2. CONCLUSIONS AND RELEVANCE: The diverse clinical phenotypes of ATXN2 CAG expansions and their coexistence in a single family are highlighted. A clinician should consider the diagnosis of spinocerebellar ataxia type 2 when encountering a patient with ataxia and a family history of ALS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959108      PMCID: PMC4039635          DOI: 10.1001/jamaneurol.2013.443

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  13 in total

1.  ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion.

Authors:  G Sorarù; M Clementi; M Forzan; V Orsetti; C D'Ascenzo; G Querin; A Palmieri; M Ermani; C Angelini; E Pegoraro
Journal:  Neurology       Date:  2011-06-07       Impact factor: 9.910

2.  ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling.

Authors:  Cinzia Gellera; Nicola Ticozzi; Viviana Pensato; Lorenzo Nanetti; Alessia Castucci; Barbara Castellotti; Giuseppe Lauria; Franco Taroni; Vincenzo Silani; Caterina Mariotti
Journal:  Neurobiol Aging       Date:  2012-03-16       Impact factor: 4.673

3.  Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis.

Authors:  Hussein Daoud; Véronique Belzil; Sandra Martins; Mike Sabbagh; Pierre Provencher; Lucette Lacomblez; Vincent Meininger; William Camu; Nicolas Dupré; Patrick A Dion; Guy A Rouleau
Journal:  Arch Neurol       Date:  2011-06

4.  Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2.

Authors:  P Van Damme; J H Veldink; M van Blitterswijk; A Corveleyn; P W J van Vught; V Thijs; B Dubois; G Matthijs; L H van den Berg; W Robberecht
Journal:  Neurology       Date:  2011-05-11       Impact factor: 9.910

5.  Ataxin-2 repeat-length variation and neurodegeneration.

Authors:  Owen A Ross; Nicola J Rutherford; Matt Baker; Alexandra I Soto-Ortolaza; Minerva M Carrasquillo; Mariely DeJesus-Hernandez; Jennifer Adamson; Ma Li; Kathryn Volkening; Elizabeth Finger; William W Seeley; Kimmo J Hatanpaa; Catherine Lomen-Hoerth; Andrew Kertesz; Eileen H Bigio; Carol Lippa; Bryan K Woodruff; David S Knopman; Charles L White; Jay A Van Gerpen; James F Meschia; Ian R Mackenzie; Kevin Boylan; Bradley F Boeve; Bruce L Miller; Michael J Strong; Ryan J Uitti; Steven G Younkin; Neill R Graff-Radford; Ronald C Petersen; Zbigniew K Wszolek; Dennis W Dickson; Rosa Rademakers
Journal:  Hum Mol Genet       Date:  2011-05-24       Impact factor: 6.150

6.  Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2.

Authors:  S M Pulst; A Nechiporuk; T Nechiporuk; S Gispert; X N Chen; I Lopes-Cendes; S Pearlman; S Starkman; G Orozco-Diaz; A Lunkes; P DeJong; G A Rouleau; G Auburger; J R Korenberg; C Figueroa; S Sahba
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

7.  ATXN-2 CAG repeat expansions are interrupted in ALS patients.

Authors:  Lucia Corrado; Letizia Mazzini; Gaia Donata Oggioni; Bernadetta Luciano; Michela Godi; Alfredo Brusco; Sandra D'Alfonso
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

8.  Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.

Authors:  Teresa Lee; Yun R Li; Caroline Ingre; Markus Weber; Torsten Grehl; Ole Gredal; Mamede de Carvalho; Thomas Meyer; Ole-Björn Tysnes; Georg Auburger; Suzana Gispert; Nancy M Bonini; Peter M Andersen; Aaron D Gitler
Journal:  Hum Mol Genet       Date:  2011-02-03       Impact factor: 6.150

Review 9.  Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.

Authors:  Nancy M Bonini; Aaron D Gitler
Journal:  J Mol Neurosci       Date:  2011-06-10       Impact factor: 3.444

10.  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.

Authors:  Andrew C Elden; Hyung-Jun Kim; Michael P Hart; Alice S Chen-Plotkin; Brian S Johnson; Xiaodong Fang; Maria Armakola; Felix Geser; Robert Greene; Min Min Lu; Arun Padmanabhan; Dana Clay-Falcone; Leo McCluskey; Lauren Elman; Denise Juhr; Peter J Gruber; Udo Rüb; Georg Auburger; John Q Trojanowski; Virginia M-Y Lee; Vivianna M Van Deerlin; Nancy M Bonini; Aaron D Gitler
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

View more
  17 in total

1.  A case of amyotrophic lateral sclerosis with intermediate ATXN-1 CAG repeat expansion in a large family with spinocerebellar ataxia type 1.

Authors:  Rossella Spataro; Vincenzo La Bella
Journal:  J Neurol       Date:  2014-06-11       Impact factor: 4.849

Review 2.  Dilemma of multiple system atrophy and spinocerebellar ataxias.

Authors:  Ming Li; Qianqian Ma; Xing Zhao; Can Wang; Huijie Wu; Jinyao Li; Wei Yang
Journal:  J Neurol       Date:  2018-04-26       Impact factor: 4.849

3.  Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.

Authors:  Leeanne McGurk; Virginia M Lee; John Q Trojanowksi; Vivianna M Van Deerlin; Edward B Lee; Nancy M Bonini
Journal:  J Neuropathol Exp Neurol       Date:  2014-09       Impact factor: 3.685

4.  Genetic analysis of ten common degenerative hereditary ataxia loci in patients with essential tremor.

Authors:  L N Clark; X Ye; X Liu; K Mirzozoda; E D Louis
Journal:  Parkinsonism Relat Disord       Date:  2015-06-06       Impact factor: 4.891

Review 5.  Frontotemporal dementia: a bridge between dementia and neuromuscular disease.

Authors:  Adeline S L Ng; Rosa Rademakers; Bruce L Miller
Journal:  Ann N Y Acad Sci       Date:  2014-12-30       Impact factor: 5.691

6.  Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.

Authors:  Jill S Goldman; Catarina Quinzii; Jane Dunning-Broadbent; Cheryl Waters; Hiroshi Mitsumoto; Thomas H Brannagan; Stephanie Cosentino; Edward D Huey; Peter Nagy; Sheng-Han Kuo
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

7.  Multiple system atrophy and repeat expansions in C9orf72--reply.

Authors:  Jill S Goldman; Sheng-Han Kuo
Journal:  JAMA Neurol       Date:  2014-09       Impact factor: 18.302

8.  Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis.

Authors:  Annalese G Neuenschwander; Khanh K Thai; Karla P Figueroa; Stefan M Pulst
Journal:  JAMA Neurol       Date:  2014-12       Impact factor: 18.302

Review 9.  Drosophila as an In Vivo Model for Human Neurodegenerative Disease.

Authors:  Leeanne McGurk; Amit Berson; Nancy M Bonini
Journal:  Genetics       Date:  2015-10       Impact factor: 4.562

10.  Phenotypic and molecular diversities of spinocerebellar ataxia type 2 in Japan.

Authors:  Rino Inada; Makito Hirano; Nobuyuki Oka; Makoto Samukawa; Kazumasa Saigoh; Hidekazu Suzuki; Fukashi Udaka; Akihiro Hashiguchi; Hiroshi Takashima; Yukihiro Hamada; Yusaku Nakamura; Susumu Kusunoki
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.